This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hood, S. Articles by Kirby, M. Search for Related Content Social Bookmarking                         What's this?

Review: PDE-5 inhibitors — a summary

Royal Alexandra Hospital, Paisley, PA2 9PN, UK

Mike Kirby

The Surgery, Nevells Road, Letchworth, Hertfordshire, SG6 4TS, UK, kirbym{at}globalnet.co.uk

The orally administered PDE-5 inhibitors have become first-line treatment for erectile dysfunction. Although the three currently available PDE-5 inhibitors have shown similar efficacy, tadalafil has a much longer half-life than sildenafil or vardenafil, and the pharmacokinetic profile of tadalafil is not affected by food. However, there is a more immediate response to dosing with sildenafil and vardenafil than tadalafil. As with all drugs, there will be individual variations in response and the physician's skill is in finding the right drug for the right patient.

Key Words: erectile dysfunction • PDE-5 inhibitors • sildenafil • vardenafil • tadalafil.

References

• Kirby M. ED as a marker for cardiovascular disease. Br J Diabetes Vasc Dis 2002;2:239-41.
• Feldman HA, Goldstein I., Hatzichristou DG, Krane RJ, McKinlay JB Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.[Web of Science][Medline] [Order article via Infotrieve]
• McCulloch DK, Campbell IV, Wu FC et al. The prevalence of diabeti impotence. Diabetologia 1980;18:279-83.[Web of Science][Medline] [Order article via Infotrieve]
• Eardley I. Pathophysiology of erectile dysfunction. Br J Diabetes Vasc Dis 2002;2:272-6.[Abstract/Free Full Text]
• Ali W., Besarani D., Kirby R. Modern treatment of erectile dysfunction. Br J Diabetes Vasc Dis 2002;2:255-61.[Abstract/Free Full Text]
• Nichols DJ, Muirhead GJ, Harness JA Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, U food effects and dose proportionality. Br J Clin Pharmacol 2002 D;53(suppl 1):55-125.
• Rajagopalan P., Mazzu A., Xia C., Dawkins R., Sundaresan P. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003;43:260-7.[Abstract/Free Full Text]
• Patterson D., Bedding A., Jewell H., Payne C., Mitchell MI The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). 4th Congress of the European Society for Sexual and Impotence Research (ESSIR), 2001; Rome, Italy.
• Moore R., Edwards J., McQuay H. Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. BMC Urol 2002;2:6.[CrossRef][Medline] [Order article via Infotrieve]
• Porst H., Rosen R., Padma-Nathan H. et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001;13:192-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hellstrom WJ, Gittelman M., Karlin G. et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002;23:763-71.[Free Full Text]
• Hellstrom WJ, Gittelman M., Karlin G. et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003;61:8-14.[Web of Science][Medline] [Order article via Infotrieve]
• Brock GB, McMahon CG, Chen KK et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002;168:1332-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Goldstein I., Lue TF, Padma-Nathan H., Rosen RC, Steers WD, Wicker PA Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338:1397-404.[Abstract/Free Full Text]
• Montorsi F., McDermott TE, Morgan R. et al. Efficacy and safety of fixeddose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology 1999;53:1011-18.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hellstrom WJ, Overstreet JW, Yu A. et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 2003;170:887-91.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Saenz de Tejada I., Angulo J., Cuevas P. et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001;13:282-90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Jackson G. Cardiovascular safety in erectile dysfunction treatment. Br J Diabetes Vasc Dis 2002;4:301-04.
• Rosen RC, McKenna KE PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes. Annu Rev Sex Res 2002; 13:36-88.[Medline] [Order article via Infotrieve]
• Cheitlin MD, Hutter AM, Jr., Brindis RG et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 1999;99:168-77.[Free Full Text]
• DeBusk R., Drory Y., Goldstein I. et al. management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton consensus panel. Am J Cardiol 2000;86:175-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 6, 383-386 (2004)
DOI: 10.1177/14746514040040060401


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hood, S. Articles by Kirby, M. Search for Related Content Social Bookmarking                         What's this?